-
COMMUNITY PHARMACY-BASED SCREENING FOR ASYMPTOMATIC ATRIAL FIBRILLATION USINGMOBILE SIX-LEAD ECG: PRELIMINARY FINDINGS
Aug 11, 2026, 17:15 PM -
NAXITAMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY HIGH-RISK NEUROBLASTOMA - A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
Aug 11, 2026, 17:15 PM -
MIXED EFFECT MODEL FOR ASSESSMENT OF TREATMENT EFFECTS WITH MISSING DATA
Aug 11, 2026, 17:15 PM -
REAL-WORLD FIRST-LINE TREATMENT (TX) PATTERNS IN ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI)-EXPERIENCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY RACE/ETHNICITY AND AREA-LEVEL SOCIOECONOMIC STATUS (SES) IN THE US
Aug 11, 2026, 17:15 PM -
SPECIALIZED RETRIEVAL-AUGMENTED GENERATION VERSUS A STANDALONE LARGE LANGUAGE MODEL FOR MARKET ACCESS QUESTIONS ON DRUG EVALUATION: A BENCHMARK AGAINST FRENCH TRANSPARENCY COMMITTEE OPINIONS
Aug 11, 2026, 17:15 PM -
CULTURAL ADAPTATION OF THE EQ-5D-Y-5L INTO AMHARIC AND TIGRINYA LANGUAGES IN ETHIOPIA
Aug 11, 2026, 17:15 PM -
ANNUAL OUT-OF-POCKET CAPS AND EQUITY-DRIVEN PATIENT COST-SHARING ACROSS EUROPEAN HEALTHCARE SYSTEMS: A 30-COUNTRY COMPARATIVE ANALYSIS
Aug 11, 2026, 17:15 PM -
AUTOMATING BRIEFING BOOK DEVELOPMENT FOR MAJOR EUROPEAN HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS USING GENERATIVE AI
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS OF IVUS-GUIDED ULTRA-LOW CONTRAST PCI IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE ACROSS THREE EUROPEAN COUNTRIES
Aug 11, 2026, 17:15 PM -
REAL-WORLD FARICIMAB DOSING INTERVALS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: ASSOCIATED REDUCTIONS IN HEALTHCARE RESOURCE USE, COSTS, AND TRAVEL-RELATED CARBON EMISSIONS
Aug 11, 2026, 17:15 PM -
POPULATION-LEVEL IMPACT OF POLATUZUMAB AND GLOFITAMAB IN ALGERIA: A 15-YEAR PROJECTION
Aug 11, 2026, 17:15 PM -
COST-EFFECTIVENESS ANALYSIS OF A RAPID MULTIPLEX PCR TEST FOR SEPSIS AND ANTIMICROBIAL RESISTANCE MANAGEMENT IN ICU PATIENTS
Aug 11, 2026, 17:15 PM -
PRE-DELIBERATIVE CONTESTABILITY FOR AI IN HEALTH TECHNOLOGY ASSESSMENT: CLOSING THE GOVERNANCE GAP AT THE AI-HTA INTERSECTION
Aug 11, 2026, 17:15 PM -
CLINICAL CHARACTERISTICS, HEALTHCARE RESOURCE USE AND COSTS AMONG CHILDREN WITH ANGELMAN SYNDROME: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS IN THE US
Aug 11, 2026, 17:15 PM -
COMPARATIVE EFFICACY AND SAFETY OF THREE CHINESE PERTUZUMAB BIOSIMILARS VERSUS REFERENCE PERTUZUMAB IN HER2-POSITIVE BREAST CANCER
Aug 11, 2026, 17:15 PM -
INFORMING SURGICAL DECISION-MAKING THROUGH EVIDENCE: A RANDOMIZED TRIAL-BASED COST-UTILITY ANALYSIS OF PERIACETABULAR OSTEOTOMY PLUS ARTHROSCOPY FOR HIP DYSPLASIA
Aug 11, 2026, 17:15 PM -
DISCONNECTION BETWEEN SYMPTOM FREQUENCY, BURDEN, AND PATIENT PRIORITIES FOR DELAYING MULTIPLE SCLEROSIS PROGRESSION: A MULTINATIONAL QUALITATIVE STUDY
Aug 11, 2026, 17:15 PM -
COST-UTILITY ANALYSIS OF ARTIFICIAL INTELLIGENCE SOFTWARE TO HELP DETECT AND CHARACTERISE COLORECTAL POLYPS
Aug 11, 2026, 17:15 PM -
HEALTHCARE RESOURCE UTILISATION IN A REAL-WORLD EUROPEAN GENERALISED MYASTHENIA GRAVIS POPULATION: PHYSICIAN-REPORTED DATA FROM FIVE COUNTRIES
Aug 11, 2026, 17:15 PM -
INDIRECT TREATMENT COMPARISON (ITC) OF MIRDAMETINIB AND SELUMETINIB FOR THE TREATMENT OF ADULTS WITH NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS (NF1-PN)
Aug 11, 2026, 17:15 PM
